BONE-MARROW-DERIVED DENDRITIC CELLS PULSED WITH SYNTHETIC TUMOR PEPTIDES ELICIT PROTECTIVE AND THERAPEUTIC ANTITUMOR IMMUNITY
BONE-MARROW-DERIVED DENDRITIC CELLS PULSED WITH SYNTHETIC TUMOR PEPTIDES ELICIT PROTECTIVE AND THERAPEUTIC ANTITUMOR IMMUNITY
复制标题
DOI：
10.1038/nm1295-1297
复制
发表时间：
1995-12-01
期刊：
影响因子：
82.9
通讯作者：
LOTZE, MT
中科院分区：
文献类型：
--
作者：
MAYORDOMO, JI;ZORINA, T;LOTZE, MT
树突状细胞是最有效的“专业”抗原呈递细胞，有望改善癌症的免疫疗法。在三种不同特征良好的肿瘤模型中，注射骨髓衍生的树突状细胞的幼稚小鼠以肿瘤相关的肽为先前被表征为1级主要的组织相容性复杂的细胞毒性T淋巴细胞，并开发了特定的特定T- Lymphocyte响应，受到保护，免受随后的致命肿瘤挑战。此外，在C3肉瘤和3LL肺癌鼠模型中，具有建立宏观肿瘤的动物（尺寸高达1 cm（2））具有肿瘤肽脉冲的树突状细胞，从而导致持续的肿瘤回归和无肿瘤的状态超过80％的病例。这些结果支持肿瘤肽脉冲的树突状细胞作为开发有效的癌症疫苗和疗法的组成部分。
Dendritic cells, the most potent 'professional' antigen-presenting cells, hold promise for improving the immunotherapy of cancer. In three different well-characterized tumour models, naive mice injected with bone marrow-derived dendritic cells prepulsed with tumour-associated peptides previously characterized as being recognized by class 1 major histocompatibility complex-restricted cytotoxic T lymphocytes, developed a specific T-lymphocyte response and were protected against a subsequent lethal tumour challenge. Moreover, in the C3 sarcoma and the 3LL lung carcinoma murine models, treatment of animals bearing established macroscopic tumours (up to 1 cm(2) in size) with tumour peptide-pulsed dendritic cells resulted in sustained tumour regression and tumour-free status in more than 80% of cases. These results support the clinical use of tumour peptide-pulsed dendritic cells as components in developing effective cancer vaccines and therapies.